$4.7 million boosts UCSD-Led Malaria Research Program

Supplemental $4.7 million will aid drug development to accelerate disease eradication

An international research team, led by principal investigator Elizabeth A. Winzeler, PhD, professor in the pediatric division of host-microbe systems and therapeutics at University of California San Diego School of Medicine, and colleagues have received a three-year, $4.7 million supplemental grant from the Bill & Melinda Gates Foundation to advance their development of improved therapies for malaria eradication and elimination.

“The very long term goals are to accelerate the development of novel treatments and preventative medicines that can be used to assist with malaria eradication and elimination, and which can serve as replacements for current drugs that are losing efficacy,” said Elizabeth Winzeler, PhD, professor of pharmacology and drug discovery at UC San Diego School of Medicine and the grant’s lead scientist.

“The grant will support a multinational consortium, with leadership at UC San Diego, which aims to speed antimalarial drug development. The objective of the consortium, which initially included the Harvard TH Chan School of Public Health, Columbia University, GlaxoSmith Kline and Washington University, is to systematically look for drug-able proteins encoded by the parasite’s genome, primarily using in vitro evolution and whole genome sequencing.”

Malaria is a global scourge. Roughly half of the world’s population live in areas at risk of malaria transmission.

 

More from CW6